METHODS: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.
RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
方法:这是一个多中心的回顾性研究,回顾了216例真菌病患者(174例),或Sézary综合征(42)在19家三级转诊教学医院单独使用贝沙罗汀或与其他疗法联合使用的10年疗程中。
结果:共包括133名男性(62%)和83名女性(38%),平均年龄63.5岁(27-95岁)。在整个研究期间,共有45%的人使用贝沙罗汀单药治疗,22%的人开始服用贝沙罗汀,但最终接受了额外的治疗,13%的人接受了另一种治疗,但最终接受了贝沙罗汀,而其余20%的人自开始以来接受了联合治疗。中位疗程为20.78个月(1-114);总有效率,70.3%。26%和45%的患者达到了完全和部分缓解率,分别。治疗耐受性良好,是最常见的毒性高甘油三酯血症(79%),高胆固醇血症(71%),和甲状腺功能减退(52%)。未报告治疗相关的5级不良事件。
结论:我们的研究证实贝沙罗汀是一种长期治疗CTCL的安全有效的疗法。